GLP-1 (S) + Cagrilinitide Blend

Description

Cagrilintide (2.5mg) / GLP-1 S (2.5mg) – Sofix Health Peptides, A two-component co-formulation of cagrilintide and a GLP-1–class peptide supplied for controlled research environments. Suitable for studies exploring amylin-receptor–related and GLP-1–receptor signaling pathways in model systems. Cagrilintide (2.5mg) / GLP-1 S (2.5mg) – Sofix Health Peptides

Composition

• Cagrilintide: 5mg

• GLP-1 S: 5 mg

• Fill volume: 2 ml vial

• Appearance: lyophilized powder in a sealed research vial

Research Focus (non-clinical)

• Combined pathway evaluation of amylin-receptor–related and GLP-1–receptor mechanisms in in-vitro or ex-vivo models

• Assay development, including chromatographic separation of two co-formulated peptides and blend ratio characterization

• Stability characterization of a two-analyte lyophilized blend under laboratory storage conditions

• Method documentation for HPLC/LC-MS identity and purity assessments

Documentation

• COA pending — third-party verification in progress

Important Notice

• For research use only

• Not for human consumption

• Not intended to diagnose, treat, cure, or prevent any disease

Quality & Manufacturing

• COA pending — third-party verification in progress

• Lyophilized for transit stability; batch traceable

• Tamper-evident seal; lot & test date on each vial

• No MOQ for online orders

• Bulk orders for physical locations start at 25-unit minimum